News

Newest uMotif product release delivers next-gen eCOA/ePRO

Steve Rosenberg joins Craig Lipset, Co-Chair DTRA to discuss his passion for patient engagement

uMotif – first new validated eCOA/ePRO innovation since paper instruments deployed on smartphones

uMotif experts to discuss the eCOA/ePRO market – what’s working, what’s wrong, and what patients need now

uMotif expands leadership team to support growth in US and EU markets

uMotif and ClinOne unify eCOA / ePRO and eConsent

$25.5m of new investment from Athyrium Capital Management fund

Achieving more meaningful patient engagement in rare disease trials

AbbVie and uMotif support rheumatoid arthritis patients with BYOD approach